Enliven Therapeutics, Inc. · NASDAQ:ELVN
Vestal Point Capital, LP reported a 5.40% stake in Enliven Therapeutics, Inc. (Schedule 13G/A)
Event Mar 31, 2026 · Filed May 15, 2026
Vestal Point Capital, LP reported a 5.40% stake in Enliven Therapeutics, Inc., 3,250,000 shares, as a passive investor on Mar 31, 2026. Filed May 15, 2026 (Schedule 13G/A).
- Stake
- 5.40%
- Shares
- 3,250,000
- Intent
- Passive
- What changed
- Stake changed
- Filed together
- 2 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| Vestal Point Capital, LP | 5.40% | 3,250,000 |
| Ryan Wilder | 5.40% | 3,250,000 |
Source
Related
- Enliven Therapeutics, Inc.
- Vestal Point Capital, LP
- Enliven Therapeutics, Inc. shareholders
- Schedule 13G · Vestal Point Capital, LP · Feb 17, 2026
- Form 4 · Hohl Benjamin · Oct 21, 2026
- Form 4 · Collins Helen Louise · Oct 21, 2026
- Form 4 · Garland J. Scott · Oct 5, 2026
- Form 4 · Hohl Benjamin · Sep 21, 2026
- Form 4 · Collins Helen Louise · Sep 21, 2026